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Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and
GNAQ have been identiﬁed in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi,
respectively.Thesemutationsarelikelytoplayacriticalroleindrivingnevogenesis.WhileeachmutationisabletoactivatetheMAP
kinase pathway, they also interact with a host of diﬀerent proteins in other pathways. The diﬀerent melanocytic developmental
pathways activated by each mutation cause the cells to migrate, proliferate, and diﬀerentiate to diﬀerent extents within the skin.
This causes each mutation to give rise to a characteristic growth pattern. The exact location and diﬀerentiation state of the cell of
origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that
most of the same developmental pathways are also present in melanoma.
1.Introduction
Nevogenesis is a multifactorial process that involves a com-
plex interplay of genetic and environmental factors. Al-
thoughweareonlyjustbeginningtounderstandthisprocess,
it is already clear that certain molecular pathways within
nevocytes need to be activated in order for nevogenesis
to occur. This paper will focus on the relevant identiﬁed
pathways that promote the development of the diﬀerent
nevus phenotypes.
2 .N evusL if eC y c l e
Benign melanocytic lesions follow an archetypal life cycle
that consists of four stages: initiation, promotion, senes-
cence, and involution. Initiation occurs when a nevus
progenitor cell acquires a mutation that will permit future
growth. Promotion occurs when the mutated cell is activated
andproliferationbegins.Thisproliferationislikelyinstigated
by a change in local environmental factors that promotes
melanocytic growth and then sustained by the previously
acquired mutation. After a period of growth, nevi stop
proliferating through the activation of senescence pathways.
This allows them to remain stable for extended periods of
time before undergoing involution.
3. Models for Nevogenesis
Current models of nevogenesis propose that melanocytic
neoplasms arise from a single cell of origin [1, 2]. However,
the diﬀerentiation state of this cell has not been clearly
established.Itisalsouncertainiftheprogenitorcellislocated
in the dermis, epidermis, or both.
One possibility is that an immature melanocytic stem
cell serves as the nevus progenitor cell. Although this
progenitor cell most likely resides in the dermis, its presence
in the epidermis can not be excluded. In this model, the
immature cell remains in a quiescent state in the skin and
acquires mutations secondary to UV light exposure or other
mutagenic processes. When environmental signals activate
this cell to produce melanocytes, an abnormal proliferation
occurs due to the genetic alterations. The speciﬁc under-
lying mutation and local environmental conditions alter
the daughter cells’ normal melanocytic diﬀerentiation and
migratory pathways in a characteristic manner. This causes
the nevus to assume a discrete phenotypic pattern.
One of the advantages of this immature progenitor
cell model is that the mutated cells can remain quiescent
until activated. This readily explains the association of
childhood sun exposure with the development of nevi
and melanoma later in life. It would also explain the2 Dermatology Research and Practice
phenomenon of eruptive nevi simultaneously growing in
response to a cytokine or an immunoregulatory medication.
Consequently, this model seems to ﬁt best with clinical
ﬁndings.
It has also been suggested that a diﬀerentiated mel-
anocyte serves as the cell of origin for melanocytic neo-
plasms. In this model, the nevogenic mutation occurs
in a diﬀerentiated melanocyte. The mutation causes the
cell to regain proliferative capacity. However, this genetic
event would also have to promote dediﬀerentiation and
the development of invasive properties in order to allow
the cell to migrate to greater depths in the dermis. In this
model, nevus growth would occur immediately after the
initial mutagenic event in either a fast or slow manner. This
is somewhat more diﬃcult to reconcile with the clinical
behavior of nevi.
As previously mentioned, both of these models are based
on nevi arising from a single cell of origin. The concept of
monoclonal origination is supported by the fact that NRAS
and BRAF mutations are almost always mutually exclusive.
However, recent studies on BRAF (reviewed below) have
documented mutation heterogeneity within nevi. There exist
at least two explanations for this phenomenon. First, an
unidentiﬁed primary mutation that impacts DNA synthesis
and repair machinery could make melanocytes more sus-
ceptible to developing BRAF mutations. Alternatively, local
environmental conditions could lead to the recruitment of
c e l l sw i t hd i ﬀerent mutations to the lesion (hamartoma).
Although a hamartoma can not be excluded, it seems likely
that there are unidentiﬁed processes occurring within these
cells that drive the heterogeneity of BRAF mutations.
4. NRAS and Congenital Nevi
NRAS is one of the three major isoforms of the RAS
family of GTPase proteins that are involved in cell growth,
diﬀerentiation, and survival. NRAS activates four major
signaling pathways: (1) RAF-MEK-ERK, (2) RalGDS, (3)
PI3K-AKT/PDK1, and (4) PLC/PKC (see Figure 1). Acti-
vation of these pathways results in a variety of diﬀerent
outcomes that include cell cycle progression, upregulated
transcription, upregulated translation, nuclear transport,
and calcium signaling. All reported NRAS gene mutations
oc curinex on2andex on3(kno wnbefor easex on1andex on
2). Approximately 65% of the mutations occur at codon 61
in exon 3, where the most frequent amino acids substitutions
are Q61K and Q61R [14]. The replacement of the glutamine
residue (Q61) with lysine (K) or arginine (R) results in
an aberrant protein that is unable to cleave GTP, and thus
the protein remains constitutively active. Although NRAS
mutations have been reported in other melanocytic nevi, the
mutation seemsto be most closely associated with congenital
melanocytic neoplasms (see Table 1)[ 11, 15–17].
In 1994, Carr and Mackie provided the ﬁrst report
documenting the presence of an activating NRAS mutation
in 28% (12 of 43) of congenital melanocytic nevi (CMN)
[3]. This ﬁnding was conﬁrmed by subsequent studies [4,
5]. Following this discovery, BRAF mutations were also
reported in CMN with incidences ranging between 39 and
86% [6–8]. However, it is important to note that all of
the aforementioned studies relied solely on histological
appearance to classify the lesions as CMN. As such, there
was no evidence that these lesions had been present at birth.
Thus, many of the specimens likely represented acquired
nevi with histological features of congenital nevi. Bauer et
al. demonstrated that using nevi with histological features of
CMN but no documentation of presence at birth introduces
a selection bias that artiﬁcially increases the incidence of
BRAF mutations in CMN [11]. Reaves et al. addressed this
issue by selecting CMN specimens whose presence were
documented in medical records at birth. None of the 36
medium and large CMN in this series possessed BRAF
mutations [9].
The following year Ichii-Nakato et al. found that 79%
(33 of 42) of small CMN and 30% (6 of 20) of medium
CMN present at birth by records or parents testimony were
BRAF positive [10]. This study demonstrated a statistically
signiﬁcant diﬀerence in the BRAF mutation rate between
small- and medium- sized CMN. The recent studies that
document CMN presence at birth have reported NRAS
mutationsin81%(26of32)[11]and70%(19of27)[11,13]
of the CMN. BRAF mutations were found in 0% (0 of 32)
[11] and 22% (6 of 27) [13] of the nevi. One report noted
that 76% (26 of 34) [12] of CMN had BRAF mutations;
however, the study contained a disproportionately high
number of small CMN.
Overall, NRAS mutations were found to exist in 55% (77
of141)oftheCMNspecimensspeciﬁcallyassayedforgenetic
NRAS abnormalities, making it the most common mutation
in CMN. BRAF mutations are also common, occurring in
39.3%(90of229)oftheCMNspeciﬁcallyassayedforgenetic
BRAF abnormalities. NRAS mutations clustered in medium
and large CMN (66%; 62 of 94 specimens studied) while
BRAF mutations clustered more frequently in the small
C M N( 7 9 % ;5 3o f6 7s p e c i m e n sd o c u m e n t e da s<1.5cm).
Thelatterassociationmaybeduetotheinclusionofacquired
nevi with histological features of congenital nevi and/or a
diﬀerence in the growth potential between the two genes.
The initiating event that causes the NRAS mutation is
not yet known. Nevertheless, it is clear that UV radiation
does not play a role in initiation given that the mutation
occurs in utero. It is also uncertain which type of cell
undergoes initiation, though it likely occurs in a neural
crest stem cell. The resultant disregulation of the neural
crest stem cell during development then leads to a massive
deposition of nevocytes along its native migration pathways
to the epidermis. The presence of NRAS mutant cells in the
dermis also appears to alter local environmental conditions
as evidenced by the presence of longer and darker hair
than the surrounding skin. BRAF mutations may also give
rise to congenital nevi, though these lesions tend to be
smaller. This may be due to the way the mutations function.
NRAS mutations favor upregulation of the CRAF isoform
of RAF over the BRAF isoform [30]. Although CRAF and
BRAFexhibitasigniﬁcantamountoffunctionalredundancy,
they have been shown to possess some unique functions
[31]. One important example of this is CRAF’s ability toDermatology Research and Practice 3
Table 1: Congenital melanocytic nevi.
Study Size studied NRAS BRAF Specimen selection
Carr and Mackie 1994 [3]T o t a l a 12 of 43 n/a Present before age 2
per parent testimony
Jafari et al. 1995 [4]T o t a l a 1 of 1 n/a Histology alone
Papp et al. 1999 [5] Total 10 of 18 Histology alone
Small 2 of 3 n/a
Medium 8 of 15
Pollock et al. 2003 [6]T o t a l a n/a 6 of 7 Histology alone
Yazdi et al. 2003 [7]T o t a l a n/a 6 of 13 Histology alone
Papp et al. 2005 [8]T o t a l a n/a 7 of 18 Histology alone
Total n/a 0 of 36
Documented in
medical records at
birth
Da Raeve et al. 2006 [9]M e d i u m 0 o f 1 0
Large 0 of 26
Total 9 of 20 39 of 62
Documented in
medical records at
birth per parent
testimony
Ichii-Nakata et al. 2006 [10] Small n/a 33 of 42
Medium 9 of 20 6 of 20
Bauer et al. 2007 [11]T o t a l b 26 of 32 0 of 32
Documented in
medical records at
birth
Bauer et al. 2007 [11]T o t a l c,d 7o f2 8 2 0o f2 8 H i s t o l o g ya l o n e
Total n/a 26 of 34
Documented in
medical records at
birth
Wu et al. 2007 [12] Small 20 of 25
Large 6 of 9
Total 19 of 27 6 of 27
Documented in
medical records at
birth
Dessars et al. 2009 [13] Medium 1 of 3 1 of 3
Large 18 of 24 5 of 24e
Totals
Total 77 of 141 (54.6%) 90 of 229 (39.3%)
Small n/a 53 of 67 (79.1%)
Medium and Large 62 of 94 (65.9%) 18 of 124 (14.5%)
(a) Size of specimens not speciﬁed; (b) all specimens either medium or large CMN; (c) all specimens small CMN; (d) not included in totals because purposely
selected for acquired nevi with congenital patterns; and (e) two of the ﬁve represent chromosomal translocation involving BRAF.
inhibit apoptosis [32]. Theoretically, inhibition of apoptosis
could allow for a greater expansion of melanocytes and thus
account for the association of NRAS mutations with larger
CMN.
In summary, activating NRAS mutations appear to be
most closely associated with the development of congenital
melanocytic nevi. This association is accentuated in the
larger lesions. BRAF mutations may also be associated with
the development of CMN. Lastly, it is likely that there
remain other unidentiﬁed mutations that contribute to the
development of CMN.
5. HRASandSpitz Nevi
HRAS is another member of the RAS protein family that is
involved in signal transduction from the cell surface to the
nucleus. Like NRAS, HRAS is able to activate all of the same
aforementioned pathways (see Figure 1). HRAS mutations
i ne x o n2a n de x o n3h a v ep r e v i o u s l yb e e nr e p o r t e di n
melanocytic lesions [17, 19]. The most frequently reported
mutation involves the replacement of a glutamine at residue
61 (Q61) of exon 3 with a lysine(K) residue [17]. This
leads to the production of an aberrant protein that can4 Dermatology Research and Practice
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Figure 1: Relative position of RAS, RAF, and GNAQ in intracellular signaling. Mutations in NRAS, HRAS<BRAF, and GNAQ lead to
alterations in transcription factor expression (MIT-F and Brn2 not shown). This in turn drives a number of processes like cell cycle
progression. The contribution of the transcription factor Myc to cell cycle progression and its relationship to tumor suppressors are shown
downstream of the aforementioned mutations.
n o tb ed e a c t i v a t e da n dt h u ss t i m u l a t e sc e l lg r o w t ha n d
diﬀerentiation.
Genetic anomalies in HRAS occur almost exclusively in
Spitz nevi (see Table 2). To date, no studies have been able
to demonstrate the presence of genetic HRAS abnormalities
in common acquired nevi, congenital nevi, or dysplastic
nevi [38, 39]. Bastian et al. ﬁrst noted HRAS copy number
ampliﬁcations in 24% (4 of 17) of unequivocally diagnosed
Spitz nevi in 1999 using comparative genomic hybridization
analysis [18]. A second larger study by Bastian et al. not only
demonstratedthepresenceofincreasedHRAScopynumbers
in 12% (12 of 102) of Spitz nevi but also established the
presence of HRAS mutations in 67% (8 of 12) of the Spitz
nevi with increased copy numbers [19].
In 2003, while trying to ascertain the speciﬁcity of the
archetypalV600EBRAFmutationasamarkerformelanoma,
Yazdi et al. demonstrated the absence of BRAF mutations in
the 69 Spitz nevi studied [7]. This ﬁnding was conﬁrmed
in multiple studies over the next two years [17, 20–24].
In the 220 Spitz nevi analyzed in these experiments, not
one harbored a BRAF mutation (see Table 2). All but one
of the studies [22] utilized microdissection techniques of
melanocytes from histological samples to decrease the rate
of false negative results. However, only one study went as far
to diﬀerentiate and include atypical Spitz nevi in the analysis
[17].
The following year two papers challenged the notion that
Spitz nevi lack BRAF mutations, showing that 21% (10 of
48) [25] and 100% (8 of 8) [26] of the specimens studied
were indeed V600E BRAF positive. However, as previously
pointed out [27, 29], one study exclusively examined Reed
nevi while the other included more atypical inﬂammatory
Spitz nevi that likely represented dysplastic nevi. Conse-
quently, it is possible that variations in histological selection
criteria created the variation in V600E BRAF positivity. This
underscores the notion that current histological evaluations
may not be the optimal method to classify nevi. Despite
the ﬂaws with these studies, it is not easy to dismiss their
ﬁndings given that Da Forno et al. and Emley et al. were
able to demonstrate the presence of a V600E BRAF mutation
in a total of 7% (3 of 42) of unequivocal Spitz nevi studied
[28, 29]. It should also be noted that 4% (4 of 98) of Spitz
nevi studied by various groups also harbored a mutation in
NRAS [17, 22, 25, 27–29].
In the series reviewed, HRAS mutations and gene
ampliﬁcationwerenotedtobepresentin0–24%ofSpitznevi
(see Table 2). However, it is likely that the reported incidence
of HRAS mutations has been artiﬁcially deﬂated by the
inclusion of certain nevi with histological classiﬁcations that
are similar but likely unrelated to Spitz nevi in the literature.
For example, when all of the specimens studied in Table 2
are considered, 49% (24 of 49) of genetic abnormalities
identiﬁed occurred in HRAS. However, when spindle cell
nevi of Reed are excluded from the specimens considered in
Table 2, HRAS-associated anomalies are found to comprise
67% (24 of 36) of the genetic abnormalities identiﬁed.Dermatology Research and Practice 5
Table 2: Spitz nevi.
Study HRAS NRAS BRAF Histological Subtypes Included
Bastian et al. 1999 [18]4 a of 17 n/a n/a Typical Spitz nevi
Bastian et al. 2000 [19]1 2 b of 102 n/a n/a Typical Spitz nevi
Yazdi et al. 2003 [7]c n/a n/a 0 of 69 Typical Spitz nevi
Palmedo et al. 2004 [20]c n/a n/a 0 of 21 Typical Spitz nevi
Mihic-Probst et al. 2004 [21]c n/a n/a 0 of 20 Typical Spitz nevi
Saldanha et al. 2004 [22]d n/a 1 of 16 0 of 26 Typical Spitz nevi
Gill et al. 2004 [23]e n/a n/a 0 of 30 Typical Spitz nevi
Turner et al. 2005 [24]d n/a n/a 0 of 24 Typical Spitz nevi
Van Dijk et al. 2005 [17]e 6f of 30 0 of 30 0 of 30 Typical and Atypical Spitz nevi
Fullen et al. 2006 [25]n / a 1 o f 4 8 1 0 g of 48 Spitz nevi and nevi of Reed
La Porta et al. 2006 [26] n/a n/a 8 of 8 Reed nevi only
Takata et al. 2007 [27] 0 of 12 0 of 12 0 of 12 Typical Spitz nevi
Da Forno et al. 2009 [28]2 h of 19 2i of 22 29 of 22 Typical and Atypical Spitz nevi
Emley et al. 2010 [29] n/a 0 of 20 1 of 20 Typical and Atypical Spitz nevi
Total (%) 24 of 180 (13.3%) 4 of 98 (4.1%) 21 of 330 (6.4%)
(a) All represent copy number increases of chromosome 11p; (b) all twelve represent copy number increases of chromosome 11p, eight of which contain
mutations; (c) scalpel used for microdissection of melanocytes from ﬁxed tissue; (d) did not utilize microdissection techniques to isolate melanocytes; (e)
laser capture used for microdissection of melanocytes from ﬁxed tissue; (f) two of the six HRAS mutations occurred in atypical nevi; (g) ﬁve of the ten BRAF
mutations occurred in atypical inﬂammatory lesions that likely represented dysplastic nevi; (h) one of the two occurred in an atypical nevus; and (i) one of
the two occurred in an atypical nevus with both BRAF and NRAS mutations.
The initiating events that lead to the development of
HRAS mutations are unknown. It is also unknown if the
progenitor cell that sustains the mutation resides in the
dermis or the epidermis, though it most likely resides
in the dermis. Despite our lack of knowledge regarding
HRAS initiation, it is clear that this mutation is associated
with a speciﬁc nevus phenotype. This is likely related
to the fact that HRAS has a signiﬁcantly higher aﬃnity
for the PI3K-PKB/AKT pathway when compared to other
RAS isoforms [41]. It would follow that preferential PI3K-
PKB/AKT activation through HRAS drives the symmetrical
overgrowth of cells with an epitheliod morphology without
marked activation of the melanizing pathways (since the
majority Spitz nevi are largely amelanotic).
In summary, approximately 13% (24 out of 180) of
unequivocal Spitz nevi studied have been shown to possess
genetic HRAS anomalies. Although the majority of genetic
abnormalities found in Spitz nevi involve HRAS, it is still
only present in small fraction of the lesions studied. Conse-
quently, it appears that HRAS is not the lone driving force
responsible for the gross and microscopic characteristics
of Spitz nevi. It is possible that unidentiﬁed mutations in
other proteins such as those present in the PI3K-PKB/AKT
pathway are responsible for the majority of Spitz nevi.
6. BRAF andMelanocyticNeoplasms
BRAF is a serine-threonine kinase that is activated by the
RAS family of proteins. Once activated, it triggers the
BRAF-MAP-ERK signaling cascade that results in the up-
regulation of proteins that lead to cell cycle progression,
transcription, and diﬀerentiation. This in turn promotes cell
growth. Although over thirty BRAF mutations are known
to exist, V600E is by far the most common variant found
in melanocytic neoplasms [42, 43]. In the BRAF V600E
mutation, a thymine at nucleotide 1799 on exon 15 is
converted into adenine, causing glutamic acid to replace
valine at residue 600. While BRAF V600E mutations have
been described in congenital nevi [13], Spitz nevi [17], and
bluenevi[22],theyhavebeenreportedtooccurwithgreatest
frequency in acquired nevi (see Table 3)[ 12].
BRAF mutations were ﬁrst described in 81% (57 of 70)
of acquired nevi studied by Pollock et al. in 2003 [6]. Since
this initial report, hundreds of acquired nevi have been
analyzed for the presence of this mutation. Overall, almost
79% (376 of 479) of the acquired nevi studied were found
to possess a mutation in BRAF. Unfortunately, not all of
the papers went on to subdivide the acquired nevi into
their histological subtypes (junctional, dermal, compound,
etc.). When the available data is compiled from the studies
in Table 3, 53% (19 of 36) of compound nevi [6, 37],
66% (2 of 3) of junctional nevi [6, 37], 65% (17 of 26)
of dysplastic/atypical nevi [6, 35], and 83% (40 of 48)
of intradermal nevi [6, 37] were found to possess BRAF
mutations. No valid conclusions can be made with regards
to the relative prevalence of BRAF mutations presented in
each subtype due to selection bias induced by the exclusion
of studies that did not publish histological subtype. Of
note, NRAS mutations were described in 4.6% (5 of 108)
of acquired nevi speciﬁcally assayed for the mutation [22,
33, 34, 37]. Less than 1% (1 of 108) of the nevi studied in
these series were found to possess both BRAF and NRAS
mutations [22, 33, 34, 37]. This is consistent with the notion
that BRAF and NRAS mutations are almost always mutually
exclusive.6 Dermatology Research and Practice
Table 3: Acquired nevi.
Study Nevi included BRAF NRAS NRAS & BRAF
Total 57 of 70 — —
Intradermal 37 of 42
Pollock et al. 2003 [6] Compound 16 of 23
Dysplastic 4 of 5
Dong et al. 2003 [33] Benign melanocytic nevi
(unspeciﬁed) 17 of 24 0 of 24 0 of 24
Saldanha et al. 2004 [22] Common acquired nevi 14 of 16 2 of 11 1 of 11
Poynter et al. 2006 [34] Benign melanocytic nevi
(unspeciﬁed) 42 of 51 3 of 51 0 of 51
Ichii-Nakato et al. 2006 [10] Common acquired nevi 105 of 120 — —
Uribe et al. 2006 [35] Total 29 of 45 — —
Common acquired nevi 16 of 24
Atypical nevi 13 of 21
Bloethner et al. 2007 [36] Benign melanocytic nevi
(unspeciﬁed) 18 of 30 — —
Wu et al. 2007 [12] Common acquired nevi 83 of 101 — —
Venesio et al. 2008 [37] Total 11 of 22 0 of 22 0 of 22
C o m p o u n d 6o f1 3 0o f1 3 0o f1 3
Intradermal 3 of 6 0 of 6 0 of 6
J u n c t i o n a l 2o f3 0o f3 0o f3
Total 376 of 479 (78.5%) 5 of 108 (4.6%) 1 of 108 (0.9%)
The initiating events that lead to the acquisition of the
BRAF V600E mutation are not known. Despite this, there
is compelling evidence that the incidence of BRAF V600E
mutations is not associated with the cumulative dose of
UV exposure. Supporting evidence includes (1) studies that
have shown that BRAF mutations occur more frequently
in areas of intermittent sun exposure than areas of chronic
sun exposure [34, 44]; (2) the fact that the V600E mutant
lacks a classic UV signature [42]; and (3) reports that have
characterized V600E mutations in CMN that developed in
utero [12]. Nevertheless, these observations do not preclude
UV exposure from contributing to the development of the
V600E mutation. This is supported by the fact that BRAF
mutations havebeen associated withUV exposure atayoung
age [45].
Thomas et al. have proposed an alternative mechanism
for UV-induced BRAF mutations. It involves UVA radiation
generating reactive oxygen species (ROS) that lead to the
formation of cyclobutane pyrimidine dimers adjacent to
nucleotide 1799. When replicative polymerase delta gets
stuck at the adjacent cyclobutane pyrimidine dimer, error-
prone polymerase eta assumes polymerase delta’s replicative
duties. This in turn would result in the commonly found
T1799A substitution [45]. If this hypothesis is true, then
the generation of ROS through any mechanism should
produce BRAF V600E mutations. It is thus interesting to
note an association between certain melanocortin-1 receptor
(MC1R) polymorphisms and the incidence of BRAF V600E
mutations [46]. This is because certain MC1R polymor-
phisms lead to increased pheomelanin production [47, 48],
and pheomelanin is known to trigger ROS production
[49].
It would be convenient to ascribe the molecular nevo-
genesis of acquired nevi to a single clonal population that
developed from an oncogenic BRAF V600E-mutation in a
single precursor cell. Unfortunately, current evidence argues
against this. It has been shown that the percentage of total
mutant alleles in BRAF V600E positive nevi varies from 5
and 40% [37]. This is much less than the 50% value that
would be seen in a population of cells derived from a single
heterozygous clone. Additionally, Lin et al. demonstrated
that BRAF V600E mutations within single nevi were often
heterozygous for a nearby single nucleotide polymorphism
[50]. This suggests that the mutation must have occurred at
least twice, once on each sister chromosome. Taken together,
the data indicates that BRAF mutations do not represent
an initiating event of nevogenesis. Instead, it is more likely
that the mutation develops as part of a secondary process
and may drive the promotion stage of nevogenesis. The
presence of polyclonal BRAF V600E mutations also favors
the supposition that an error-prone polymerase may be
responsible for inserting an adenosine at nucelotide 1799
when it is invoked by oxidative stress. It is also possible that
ad i ﬀerent initiating mutation will be identiﬁed that creates
a pro-BRAF V600E mutagenic environment in the acquired
nevi. This would allow for a single clonal population
especially prone to V600E mutations to be responsible for
nevogenesis.
Insummary,approximately79%(376of479)ofacquired
nevi harbor BRAF mutations. The polyclonal nature of theseDermatology Research and Practice 7
Table 4: Blue nevi.
GNAQ BRAF NRAS HRAS
Yazdi et al. 2003 [7]— 0 o f 2 0 — —
Saldanha et al. 2004 [22]— 3 o f 2 5 0 o f 1 5 —
Van Raamsdonk et al. 2009 [40]2 4 o f 2 9 — — —
Total 24 of 29 (82.8%) 3 of 45 (6.7%) 0 of 15 (0%) —
Table 5: Summary of common mutations found in congenital,
spitz, acquired, and blue nevi.
Classiﬁcation Mutations and Relative Frequency
Congenital nevi NRAS > BRAF
Spitz nevi HRAS > BRAF > NRAS
Acquired nevi BRAF > NRAS
Blue nevi GNAQ > BRAF
BRAF mutations suggests that they represent a secondary
event driving the promotion phase of nevogenesis. As such,
the underlying initiating events that drive nevogenesis in
acquired nevi remain to be identiﬁed.
7.GNAQandBlue Nevi
GNAQ encodes an alpha subunit of the heterotrimeric
G-protein responsible for transducing signals between G-
protein couples receptors (GPCRS) and their downstream
eﬀectors. These eﬀectors include but are not limited to the
PLC/PKC and RAF-MEK-ERK pathways that also sit down-
stream of RAS [51]. GNAQ mutations almost exclusively
involve the replacement of a glutamine residue at codon 209
of exon 5 by either leucine (51%) or proline (47%) residues
[40, 52–54]. The aﬀected residue is present in the ras-like
domain of GNAQ and corresponds to the Q61 mutation
found in NRAS and HRAS [40].
Few investigators have studied the genetic proﬁles of
blue nevi. Combined data from these studies indicates that
GNAQ is by far the most common genetic anomaly (82.8%);
BRAF V600E mutations are rare (6.7%); NRAS mutations
have not been have not yet been identiﬁed (see Table 4)
[7, 22, 40]. Van Raamsdonk et al. have also reported one
GNAQ mutation in seventeen nevi of Ota studied [40]. No
studies have identiﬁed the presence of GNAQ mutations in
other benign melanocytic tumors [39].
TheinitiatingeventsthatleadtotheacquisitionofGNAQ
mutations are unknown. Although this mutation does not
bear a classic UV signature, oxidative stress, possibly from
UVA exposure, could play a role. The GNAQ mutation
most likely occurs in a dermal melanocytic precursor as no
epidermal component is present in the majority of lesions.
This is consistent with what is known to occur in mice
where the GNAQ mutation has been shown to lead to the
accumulation of dermal melanin [51].
8. Conclusion
All of the previously discussed activating mutations occur
in proteins that are components of complex cellular trans-
duction pathways that exhibit a fair amount of overlap and
redundancy (see Figure 1). As a result, NRAS, HRAS, BRAF,
andGNAQareallabletoalterexpressionpatternsofmultiple
transcription factors like Jun, Fos, Myc, NFκB, Brn2, and
MITF. These transcription factors in turn drive proliferation,
diﬀerentiation, and senescence [55–57]. Despite the fact
that NRAS, HRAS, BRAF, and GNAQ are involved in
convergent pathways, mutations in these genes result in
diﬀerent cellular eﬀects. This can be attributed to the various
positions of each gene product in the pathways and diﬀerent
speciﬁcities for downstream eﬀector molecules [41, 58]. This
in turn results in each speciﬁc mutation generating its own
characteristic growth pattern. The growth patterns may be
further inﬂuenced by the location and the developmental
stage of the cell of origin.
The role of each of these mutations in nevus initiation
and promotion has yet to be fully elucidated. It is likely
that the acquisition of NRAS, HRAS, and GNAQ muta-
tions represents the initiating event that primes a nevus
progenitor cell to respond abnormally to normal melanocyte
recruitment signals. Mutations in BRAF are more likely
to represent secondary events in nevogenesis given their
polyclonal nature. As such, BRAF mutations probably play
a major role in acquired nevus growth promotion.
NRAS, HRAS, and BRAF are all components of the
mitogenic RAS-RAF-MEK-ERK pathway known to promote
cellular proliferation [55]. GNAQ is also able to upregulate
the RAF-MEK-ERK pathway via PKC [52]. Consequently,
mutations in all of the respective gene products have the
potential to promote melanocytic proliferation. However, it
is also possible these mutations function to sustain growth
promotion once another, earlier event, such as a change
in extracellular signaling, induces the recruitment of the
mutated melanocyte.
All of these mutations have also been described in
melanoma. The discriminating feature that distinguishes
these benign nevi from melanoma is the induction of senes-
cence pathways that signal growth arrests. This terminates
the promotion phase and prevents indeﬁnite proliferation.
In conclusion, NRAS, HRAS, BRAF, and GNAQ have
been identiﬁed in benign nevi, and their presence roughly
correlates with congenital, Spitz, acquired, and blue nevi,
respectively, (Table 5). In the future, dermoscopy and other
noninvasive invivo imaging technologies may allow us to
better predict which lesions harbor a speciﬁc mutation.8 Dermatology Research and Practice
There is still much to be learned about how these mutations
occur, as well as the developmental stage and location of the
progenitor cell. Since these mutations can also be found in
melanoma, a further understanding of nevogenesis will have
a direct impact on melanoma research eﬀorts.
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